Production (Stage)
Cellectar Biosciences, Inc.
CLRB
$0.3822
-$0.031-7.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -180.38% | 83.94% | -1,495.03% | 96.55% | -238.05% |
| Total Depreciation and Amortization | -17.93% | 0.00% | 3.94% | -25.42% | 26.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 110.75% | -367.13% | 127.54% | -175.44% | 558.17% |
| Change in Net Operating Assets | -5,806.29% | -102.86% | 234.97% | 26.40% | -241.37% |
| Cash from Operations | 14.02% | -19.05% | 35.18% | -5.83% | -39.25% |
| Capital Expenditure | -- | -- | 100.00% | 1.39% | 91.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | 1.39% | 91.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -100.00% | 94.10% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -100.00% | -- | -100.00% | 9,843.20% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14.50% | -230.74% | 159.27% | -146.49% | 423.37% |